Melanoma Clinical Trials

Showing 341-360 of 1,477 trials

Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma

NCT05303493

Modulating the gut microbiome to improve response to immune-checkpoint inhibitors is an active area of study. Prebiotic substances (compounds which positively shift the gut microbiome) are a reliable and safe method of gut microbiome modulation. Data suggest that the berry Camu Camu (CC), also known as Myrciaria dubia has prebiotic potential to enrich Akkermansia muciniphila, a bacterium shown to alleviate metabolic disorders and improve ICI efficacy in preclinical models. Our primary objective is to assess the safety and tolerability of CC prebiotic in patients with advanced NSCLC and melanoma in combination with standard-of-care ICI.

NSCLC Stage IVMelanoma Stage IVUnresectable Melanoma+1 more

Centre hospitalier de l'Université de Montréal (CHUM)45 participantsStarted Jun 2022

Longueuil, Quebec, Canada • Montreal, Quebec, Canada • Montreal, Quebec, Canada

Active Not RecruitingNA

eFLASH for Skin Lesions of Malignant Melanomas

NCT06549439

This prospective single center phase I trials aims to assess feasibility and safety of electron FLASH RT for treatment of melanoma skin metastases. Feasibility will be defined as FLASH delivery with an accuracy of +/-10% for each fraction, safety will be confirmed if a maximum of 2 out of 6 patients develop dose limited toxicity.

Metastatic Melanoma

University of Zurich10 participantsStarted Jan 2024

Zurich, Canton of Zurich, Switzerland

Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma

eFLASH for Skin Lesions of Malignant Melanomas

Related Searches

ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

OH2 Injection in Melanoma

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

OH2 Injection in Combination With HX008 for Melanoma.

Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

An International Study on Pediatric Patients With Rare Tumors.

Implementation of Teledermoscopy and Artificial Intelligence

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Adding IL-2 to Tebentafusp to Eradicate Cancer Progression

Observational Study of Nivolumab Monotherapy or in Combination With Ipilimumab in Participants With Advanced Melanoma and in Participants With Adjuvant Nivolumab Therapy

Evaluation of Skin Tests in Biotherapy Allergies

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma